03 July 2025
03 July 2025
Lynozyfic can be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.
GlobalData analysis shows the HIV pre-exposure prophylaxis sector is not being maximised in the US.
Adagene retains global commercial rights to muzastotug.
Zegfrovy is designed to target a broad range of EGFR mutations while maintaining selectivity over wild-type EGFR.
The UK Government is pushing for a single, unified digital patient record within the NHS.
Ligand will receive a 13% royalty on global net sales of Zelsuvmi.
Research by non-partisan think-tank CBO forecasts that the bill’s massive cuts to Medicaid could leave 11.8 million Americans without health insurance by 2034.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
